Beijing Med-Pharm Corporation (NASDAQ: BJGP) announced on October 5 that it had named pharmaceutical executive Yanping Zhao to the new post of Corporate Vice President.

Serving as the chief representative for Beijing Med-Pharm in China, Mme. Zhao will work with David Gao, CEO of Beijing Med-Pharm, to oversee and coordinate all the Company's Chinese subsidiaries. She will also have responsibility for corporate strategic business development, including merge.

Mme. Zhao joined Beijing Med-Pharm from China Biopharmaceutical Limited, a Hong Kong Exchange-listed company, where she served as Vice President, Executive Director and Chief Representative of the Beijing Office. While at China Biopharmaceutical in 2005, Mme. Zhao was instrumental in establishing, developing and selling 55% of Shandong China Tai Freda Pharmaceutical to Bausch & Lomb for $200 million, which at the time was the largest pharmaceutical merger and acquisition ever in China.